がん免疫療法 - 自家がんワクチン

Authors: Noriaki SAKAMOTO, Eiichi ISHIKAWA, Tetsuya YAMAMOTO, Kaishi SATOMI, Kei NAKAI, Masayuki SATO, Takao ENOMOTO, Yukio MORISHITA, Shingo TAKANO, Tadao OHNO, Koji TSUBOI, and Akira MATSUMURA

Journal: Neurol Med Chir (Tokyo) 51, 319-325, 2011

Abstract: Temozolomide (TMZ), an alkylating agent widely used for patients with glioblastoma multiforme (GBM), has the potential to enhance the acquired immune response to GBM. However, there are only a few reports of GBM cases treated with vaccine-based immunotherapy combined with or after TMZ. Here, we report describe 3 cases of GBM patients treated with autologous formalin-fixed tumor vaccine (AFTV) combined with TMZ. All cases demonstrated pathological changes associated with the therapy. After a 4-week break from the standard initial treatments, 1 patient with primary GBM patient and 2 patients with secondary GBM patients received adjuvant TMZ for 5 days combined with AFTV injection and were subsequently treated with multiple cycles of adjuvant TMZ alone for 5 days every 28 days (AFTV/TMZ therapy). Adverse effects related to AFTV plus TMZ were very minor in all cases patients. Magnetic resonance imaging revealed partial response in 2 cases patients. CD3+CD8+ lymphocytes were frequently detected in surgical specimens and MIB-1 labeling index in 2 cases decreased after the AFTV/TMZ therapy. The AFTV/TMZ therapy will therefore be feasible to submit is suitable for larger scale clinical trials.